Table 1.
Baseline characteristics
| Variable | WBRT+placebo (n = 40)* | WBRT+erlotinib (n = 40)† |
|---|---|---|
| No. (%) | No. (%) | |
| Age at random assignment, y | ||
| Median | 62.2 | 61.3 |
| Range | 41 - 73 | 48 - 75 |
| Sex | ||
| Female | 19 (47.5) | 25 (62.5) |
| Male | 21 (52.5) | 15 (37.5) |
| Age-modified RTOG RPA‡ | ||
| I | 8 (20.0) | 10 (25.0) |
| II | 32 (80.0) | 30 (75.0) |
| Brain metastases, no. | ||
| ≤3 | 26 (65.0) | 23 (57.5) |
| >3 | 14 (35.0) | 17 (42.5) |
| Extra-cranial metastases | ||
| Absent | 16 (40.0) | 15 (37.5) |
| Present | 24 (60.0) | 25 (62.5) |
| Karnofsky performance score | ||
| 70 | 13 (32.5) | 9 (22.5) |
| 80 | 15 (37.5) | 22 (55.0) |
| 90 | 9 (22.5) | 9 (22.5) |
| 100 | 3 (7.5) | 0 (0.0) |
| Histology | ||
| Adenocarcinoma | 20 (50.0) | 23 (57.5) |
| Squamous | 7 (17.5) | 5 (12.5) |
| Other | 6 (15.0) | 5 (12.5) |
| Unspecified | 7 (17.5) | 7 (17.5) |
* One patient died before treatment, and one patient progressed before treatment.
† Three patients died before treatment.
‡ Radiation Therapy Oncology Group Recursive Partitioning Analysis.